MiddleBrook Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 9, 2007
07 11월 2007 - 5:14AM
PR Newswire (US)
Conference Call and Webcast to Follow GERMANTOWN, Md., Nov. 6
/PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc.
(NASDAQ:MBRK), a pharmaceutical company focused on developing and
commercializing novel anti-infective products, today announced it
will release results for the quarter ended September 30, 2007, on
Friday, November 9, 2007, before the market opens. A full text copy
of the release will be disseminated at that time. Edward M. Rudnic,
Ph.D., president and chief executive officer, will host a
conference call to discuss the results and other corporate
developments at 10:30 AM ET on Friday, November 9, 2007. Also
participating on the call will be Robert C. Low, vice president,
finance and CFO. To participate in the conference call, dial the
appropriate number below shortly before the 10:30 AM start time and
ask for the MiddleBrook Pharmaceuticals conference call hosted by
Dr. Rudnic. The teleconference dial-in numbers are as follows:
Domestic callers 1-800-813-8504 International callers
1-706-643-7752 The conference call will be broadcast simultaneously
and archived on the Company's web site,
http://www.middlebrookpharma.com/. Investors should go to the web
site at least 15 minutes early to register, download, and install
any necessary audio software. A replay of the call will be
available on Friday, November 9, 2007, beginning at 12:30 PM ET and
will be accessible until Friday, November 16, 2007, at 5:00 PM ET.
The replay call-in number is 1-800-642-1687 for domestic callers
and 1-706-645-9291 for international callers. The access number is
23072308. About MiddleBrook Pharmaceuticals: MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRKNASDAQ:formerlyNASDAQ:Advancis
PharmaceuticalNASDAQ:Corporation) is a pharmaceutical company
focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the
treatment of infectious disease. The Company is developing a
portfolio of anti-infective drugs based on its novel biological
finding that bacteria exposed to antibiotics in front-loaded
staccato bursts, or "pulses," are killed more efficiently and
effectively than those under standard treatment regimens. Based on
this finding, MiddleBrook has developed a proprietary, once-a-day
pulsatile delivery technology called PULSYS(TM). By examining the
resistance patterns of bacteria and applying its delivery
technologies, MiddleBrook has the potential to redefine infectious
disease therapy and significantly improve drug efficacy, shorten
length of therapy, and reduce drug resistance versus currently
available antibacterial products. For more on MiddleBrook, please
visit http://www.middlebrookpharma.com/. DATASOURCE: MiddleBrook
Pharmaceuticals, Inc. CONTACT: Bob Bannon, Vice President, Investor
Relations & Corporate Communications of MiddleBrook
Pharmaceuticals, Inc., +1-301-944-6710, Web site:
http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Middlebrook Pharmaceuticals (MM) News Articles